MDMarc Decramer

Marc Decramer

*This is an algorithmically generated author record based on publicly available information.

Marc Decramer has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The minimal important difference of the pulmonary functional status and dyspnea questionnaire in patients with severe chronic obstructive pulmonary disease

    by Eloisa Mg Regueiro, Chris Burtin, Paul Baten, Daniel Langer, Hans Van Remoortel, Valéria A Pires Di Lorenzo, Dirceu Costa, Wim Janssens, Marc Decramer, Rik Gosselink, et al.

    Background: The modified version of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ-M) is used in patients with COPD to obtain information about their functional status. It consists of 3 components (change in activities, dyspnea and fatigue) ranging from 0 to 100 and has been shown to be responsive following pulmonary rehabilitation (PR). The interpretation of changes in PFSDQ-M score after an intervention is difficult in the absence of the minimal important difference (MID) of the PFSDQ-M. This study aims at investigating the MID of the PFSDQ-M. Methods: We enrolled 301 patients with COPD (FEV1 42 ± 15%pred) that completed the PFSDQ-M before and after a 3-month PR program (∆Chronic Respiratory Disease Questionnaire (CRDQ) +16 ± 12 points, ∆Six-minute walking distance (6MWD) +47 ± 89 m, both p < 0.001). An anchor-based approach consisted of calculating the correlation between the ∆PFSDQ-M and anchors with an established MID (∆CRDQ and ∆6MWD). Linear regression analyses were performed to predict the MID from these anchors. Secondly several distribution-based approaches (Cohen’s effect size, empirical rule effect size and standard error of measurement method) were used. Results: Anchor-based estimates for the different PFSDQ-M-components were between −3 and −5 points based on CRDQ score and −6 (only calculated for change in activities) based on 6MWD. Using the distribution-based methods, the estimates of MID ranged from −3 to −5 points for the different components. Conclusions: We concluded that the estimate of MID of the PFSDQ-M after pulmonary rehabilitation corresponds to a change of 5 points (range - 3 to −6) in each component in patients with severe COPD.


  • Open Access

    Impact of exacerbations of cystic fibrosis on muscle strength

    by Chris Burtin, Hans Van Remoortel, Bart Vrijsen, Daniel Langer, Kristine Colpaert, Rik Gosselink, Marc Decramer, Lieven Dupont, Thierry Troosters

    Adult patients with cystic fibrosis have peripheral muscle weakness, which is related to exercise intolerance and poor prognosis. The influence of acute exacerbations on muscle strength has been poorly studied. This study aimed to investigate whether quadriceps force (QF), as assessed with an involuntary technique, changes during intravenous antibiotics therapy (IVAT) for an exacerbation. QF was measured in 20 patients using twitch stimulation of the femoral nerve at the day of hospitalization (day 1) and at termination (day 14) of the IVAT. Physical activity was monitored during IVAT using a SenseWear armband. Ten stable patients served as control subjects. QF did not change during exacerbation (potentiated twitch force at day 1: 140 ± 42 N, at day 14: 140 ± 47 N), but a decrease was observed in individual patients. Changes in twitch force during exacerbation were correlated with time spent in activities of at least moderate intensity (r = 0.61, p = 0.007). QF does not systematically decrease during exacerbations of cystic fibrosis. Individual changes in QF are well correlated with daily time spent in activities of at least moderate intensity.


  • Open Access

    Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

    by Nicola A Hanania, Amir Sharafkhaneh, Bartolome Celli, Marc Decramer, Ted Lystig, Steven Kesten, Donald Tashkin

    Debate continues as to whether acute bronchodilator responsiveness (BDR) predicts long-term outcomes in COPD. Furthermore, there is no consensus on a threshold for BDR.


  • Open Access

    The impact of care pathways for exacerbation of Chronic Obstructive Pulmonary Disease: rationale and design of a cluster randomized controlled trial

    by the EQCP Study Group, Kris Vanhaecht, Walter Sermeus, Jan Peers, Cathy Lodewijckx, Svin Deneckere, Fabrizio Leigheb, Marc Decramer, Massimiliano Panella

    Hospital treatment of chronic obstructive pulmonary disease (COPD) frequently does not follow published evidences. This lack of adherence can contribute to the high morbidity, mortality and readmissions rates. The European Quality of Care Pathway (EQCP) study on acute exacerbations of COPD (NTC00962468) is undertaken to determine how care pathways (CP) as complex intervention for hospital treatment of COPD affects care variability, adherence to evidence based key interventions and clinical outcomes.